Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : EMA - Increased manufacturing capacity and supply for Spikevax

08/02/2021 | 11:32am EDT

EMA's human medicines committee (CHMP) has approved a scale-up of the active substance production process at Moderna's COVID-19 vaccine manufacturing sites in the United States (US).

This recommendation is expected to have significant impact on the supply of Spikevax, the COVID-19 vaccine developed by Moderna, in the European Union. It is estimated that in the third quarter of 2021, the US supply chain will provide 40 million doses of vaccine for the European market.

EMA's decision reaffirms that the two recently approved US facilities, ModernaTX, Inc. in Norwood, Massachusetts and Lonza Biologics, Inc. in Portsmouth, New Hampshire, are capable of consistently manufacturing high-quality active substance and will enable Moderna to increase production capacity at these sites.

Since the granting of a conditional marketing authorisation for Spikevax, the CHMP authorised a total of four manufacturing sites for the production of active substance for this vaccine, two in the US as mentioned above, and two in Visp, Switzerland.

This recommendation does not require a European Commission decision.

Contact:

Tel: +31 (0)88 781 8427

Email: press@ema.europa.eu

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about MODERNA, INC.
04:25pMODERNA : Canada paused COVID-19 vaccine deliveries as supply far exceeds demand
AQ
02:58pMODERNA : COVID SCIENCE-Severe COVID-19 may trigger autoimmune conditions; New variants ca..
RE
02:48pMODERNA : U.S. CDC advisers could vote on Pfizer COVID-19 vaccine booster on Thursday
RE
08:29aWHITE HOUSE REPORTEDLY URGED PFIZER : NY Times
MT
12:17aIndia Unlikely to Order Pfizer, Moderna COVID-19 Jabs As Local Vaccine Output Soars
MT
09/21MODERNA : Brazil and Argentina tapped to make mRNA vaccines in Latin America
RE
09/21MODERNA : U.S. administers 386.8 mln doses of COVID-19 vaccines - CDC
RE
09/21MODERNA : U.S. CDC Says Delivered 467,249,715 Doses Of Covid-19 Vaccine As Of Sept 21
RE
09/21Shangula Rages Against West's Vaccine Nationalism
AQ
09/21Johnson & Johnson Data Shows COVID-19 Booster Shots 94% Effective Against Moderate to S..
MT
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 20 348 M - -
Net income 2021 12 529 M - -
Net cash 2021 12 947 M - -
P/E ratio 2021 14,6x
Yield 2021 -
Capitalization 175 B 175 B -
EV / Sales 2021 7,97x
EV / Sales 2022 7,37x
Nbr of Employees 1 300
Free-Float 90,3%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MRNA | US60770K1079 | MarketScreener
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 16
Last Close Price 434,04 $
Average target price 306,23 $
Spread / Average Target -29,4%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.315.47%175 199
LONZA GROUP AG33.09%60 866
IQVIA HOLDINGS INC.43.03%49 103
CELLTRION, INC.-23.26%31 708
SEAGEN INC.-5.78%30 021
PHARMARON BEIJING CO., LTD.81.89%25 723